This study ultimately led to other phase II clinical trials investigating the anti-tumour activity and safety of other anti-androgen agents such as enzalutamide and abiraterone acetate (a selective inhibitor of CYP17) among AR-positive TNBC patients [55,56]. The gene discussed is AR; the disease is neoplasm.